Deutsche Bank analyst Brad Zelnick downgrades Check Point Software (NASDAQ:CHKP) from Buy to Hold and lowers the price target from $160 to $150.
Cannabis Terpenes Reduce Inflammation, Says Gb Sciences Study
Gb Sciences, Inc. (OTCQB: GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, co-published a study that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation.